Brian Rifkin

September 28, 2025

Background, summary

Chimerism and Immune Tolerance: Can We Says Goodbye to Immunosuppression?

Brian Rifkin

September 28, 2025

Background, summary

Chimerism and Immune Tolerance: Can We Says Goodbye to Immunosuppression?

This week, we will discuss the use of creating chimeras to induce immune tolerance and its potential to decrease or eliminate the need for immunosuppression in kidney transplant recipients.

swapnil hiremath

May 12, 2025

Background

Double Trouble: ddAVP and the Bleeding Biopsy

swapnil hiremath

May 12, 2025

Background

Double Trouble: ddAVP and the Bleeding Biopsy

This week, we will discuss a double header: two single centre ddAVP trials in kidney biopsy from India.

swapnil hiremath

January 21, 2025

Background

HOPE-ing and Coping with Pain in Dialysis

swapnil hiremath

January 21, 2025

Background

HOPE-ing and Coping with Pain in Dialysis

This week, we will discuss the HOPE trial - no not that one - the one in dialysis that was a LBCT in 2024. Should we look beyond analgesics to non-pharmacological options more seriously?

swapnil hiremath

December 2, 2024

Background

BPROAD: Sprinting down the BP Road in Diabetes

swapnil hiremath

December 2, 2024

Background

BPROAD: Sprinting down the BP Road in Diabetes

This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.

Brian Rifkin

November 18, 2024

Background

Potassium Rollercoaster Heartbreak

Brian Rifkin

November 18, 2024

Background

This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.

swapnil hiremath

August 5, 2024

Background

Trial by Combat: Do Amino Acids provide PROTECTION to the Kidneys?

swapnil hiremath

August 5, 2024

Background

Trial by Combat: Do Amino Acids provide PROTECTION to the Kidneys?

This week, we will discuss an intriguing hypothesis for many nephrologists: can amino acids prevent acute kidney injury?

swapnil hiremath

June 11, 2024

Background

FLOWing with the SemagluTIDE

swapnil hiremath

June 11, 2024

Background

This week, we will discuss the blockbuster trial of 2024, FLOW. GLP1RAs have arrived in the nephrology realm.

swapnil hiremath

April 9, 2024

Background

Healing, Hype, or Harm: The NefIgArd trial

swapnil hiremath

April 9, 2024

Background

Healing, Hype, or Harm: The NefIgArd trial

This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?

swapnil hiremath

January 9, 2024

Background

Two’s Company but Three maybe the Winner? Aldosterone Synthase Inhibition added to RASi + Flozin

swapnil hiremath

January 9, 2024

Background

Two’s Company but Three maybe the Winner? Aldosterone Synthase Inhibition added to RASi + Flozin

This week we will discuss the article from Lancet on the addition of an ASI to background RASi and empagliflozin. Did this work?

swapnil hiremath

December 5, 2023

Background

Zibotentan and Flozins: Climbing to the ZENITH of nephroprotection?

swapnil hiremath

December 5, 2023

Background

Zibotentan and Flozins: Climbing to the ZENITH of nephroprotection?

This week, we will discuss yet another endothelin antagonist trial, on a background of flozins, in proteinuric CKD. Will flozins help breakthrough the endothelin badness?

Cristina Adriana Popa

July 11, 2023

Background

HDF vs HD: Need for CONVINCE-ing Evidence

Cristina Adriana Popa

July 11, 2023

Background

HDF vs HD: Need for CONVINCE-ing Evidence

This week, we will discuss CONVINCE, a randomized controlled trial, about the long-lasting battle between hemodialysis and hemodiafiltration. Will it convince the unconvinced, or will it diffuse even more uncertainty into community?

swapnil hiremath

May 23, 2023

Background

SPARE a Thought for SPARSENTAN?

swapnil hiremath

May 23, 2023

Background

This week, we will discuss another IgA Nephropathy trial - Sparsentan this time. A dual endothelin antagonist and angiotensin receptor antagonist.

swapnil hiremath

May 9, 2023

Background

Rituximab, Remission, and Relapses in ANCA Vasculitis

swapnil hiremath

May 9, 2023

Background

Rituximab, Remission, and Relapses in ANCA Vasculitis

This week, we will discuss the resounding triumph of rituximab in maintenance therapy for ANCA-associated vasculitis. RIP Azathioprine?

swapnil hiremath

March 28, 2023

Background

MMF in IgA: Inching into the MAINstream?

swapnil hiremath

March 28, 2023

Background

MMF in IgA: Inching into the MAINstream?

This week, we will discuss the MAIN trial of MMF monotherapy in IgA Nephropathy. Pairs nicely with the NephMadness IgA Region discussion!

swapnil hiremath

January 24, 2023

Background

CARDINAL Sin: Bardoxolone and Alport Syndrome

swapnil hiremath

January 24, 2023

Background

CARDINAL Sin: Bardoxolone and Alport Syndrome

This week, we will discuss the largest trial conducted in Alport syndrome. Positive results, but rejected by the FDA. Did they make the right call?

swapnil hiremath

December 6, 2022

Background

PRECISION Targeting in Resistant Hypertension

swapnil hiremath

December 6, 2022

Background

PRECISION Targeting in Resistant Hypertension

This week, we will discuss the first new BP lowering drug in decades. Aprocitentan, a dual endothelin antagonist in a meticulously designed trial in resistant hypertension.

swapnil hiremath

November 13, 2022

Background

EMPA-Kidney: ‘Empa’sizing the role of Flozins in Chronic Kidney Disease

swapnil hiremath

November 13, 2022

Background

EMPA-Kidney: ‘Empa’sizing the role of Flozins in Chronic Kidney Disease

This week, we will discussing the EMPA-Kidney Study! Expanding flozin kidney protection to a lower level of GFR and albuminuria.

joel topf

September 19, 2022

Background

ADVOR TRIAL - Can the addition of a little buddy make a big difference ?

joel topf

September 19, 2022

Background

ADVOR TRIAL - Can the addition of a little buddy make a big difference ?

This week, we will discuss The ADVOR trial, possibly the only randomized, placebo controlled trial of sequential nephron blockade ever. Could the use of acetazolamide in acute decompensated heart failure make a difference?

swapnil hiremath

March 6, 2022

Background

Pain, Paracetamol and Pressure

swapnil hiremath

March 6, 2022

Background

This week, we will discuss the PATH BP trial, which demolishes the supposed benign nature of acetaminophen/paracetamol.

swapnil hiremath

December 7, 2021

Background

Old is Gold: CLICK for Chlorthalidone

swapnil hiremath

December 7, 2021

Background

This week, we will discuss the CLICK trial. Another medical reversal - showing that this old and cheap drug, chlorthalidone, might actually work in advanced CKD. Click through to read more.